List view / Grid view
Hal V. Barron (born 1962) is an American clinician-scientist and drug developer currently serving as president of research and development at Calico. He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.
Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs. In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.
Barron’s current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 90 papers in peer-reviewed scientific journals. He was a member of the board of directors at Alexza Pharmaceuticals.
Updated survival results from the Phase III EMILIA study...
1 October 2012 | By Roche
Updated survival results from the Phase III EMILIA study...
Final results from the Phase III HERA trial...
1 October 2012 | By Roche
Final results from the Phase III HERA trial...
Pivotal study met co-primary efficacy endpoint of overall survival...
27 August 2012 | By Roche
Pivotal study met co-primary efficacy endpoint of overall survival...
First major treatment advance in more than 25 years for…
13 August 2012 | By Roche
First major treatment advance in more than 25 years for sight-threatening condition...
Phase III study met its co-primary endpoint...
10 August 2012 | By Roche
Phase III study met its co-primary endpoint...
“We are pleased that Perjeta helped people with HER2-positive metastatic…
22 June 2012 | By Roche
“We are pleased that Perjeta helped people with HER2-positive metastatic breast cancer..."
Roche announced that the U.S. FDA has approved PerjetaTM (pertuzumab)...
11 June 2012 | By Roche
Roche announced that the U.S. FDA has approved PerjetaTM (pertuzumab)...
Data announced from the ADACTA study...
6 June 2012 | By Roche
Data announced from the ADACTA study...
Phase III data on Avastin in advanced colorectal and ovarian…
16 May 2012 | By Roche
Phase III data on Avastin in advanced colorectal and ovarian cancers...
Roche announced that following the results of the second interim…
7 May 2012 | By Roche
Roche announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III trial...
Roche announced that the SUMMACTA study met its primary endpoint...
3 May 2012 | By Roche
Roche announced that the SUMMACTA study met its primary endpoint...
Roche have announced topline results of EMILIA...
30 March 2012 | By Roche
Roche have announced topline results of EMILIA...
Roche announced preliminary results from the ADACTA study...
2 March 2012 | By Roche
Roche announced preliminary results from the ADACTA study...
First and only personalized skin cancer medicine allows people with…
20 February 2012 | By Roche
First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live significantly longer...
The U.S. FDA has accepted the company’s Biologics License Application…
8 February 2012 | By Roche
The U.S. FDA has accepted the company’s Biologics License Application for pertuzumab...
